A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.

Inclusion Criteria:

• Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
• Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
• Participants must have an ECOG performance status of less than or equal to 1
• Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1

Exclusion Criteria:

• Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
• Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
• Participants must not have a history of allergy to any of the study treatment components